An interventional study of Combiner whole genome and RNA sequencing in Parkinson's Disease, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by University Hospital, Strasbourg, France · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 428 studies in Parkinson Disease with a site in France — 63 open to participants now, 76 under way, 4 of them phase 3. Parkinson Disease · France.
Among the 428 studies in Parkinson Disease with a site in France, this one is the 293rd largest by planned enrollment of the 328 interventional ones that give a count, is one of 17 that started in 2025, is one of 179 with no phase, reaches primary completion later than 34 of the 75 other live ones, and was the 394th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →63 of the 428 studies in Parkinson Disease with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital Tuebingen · Sites in France, Germany, Italy and 4 more countries
Ages 35–80
Hospices Civils de Lyon · Sites in France
Ages 20–80 · Healthy volunteers
University Hospital, Grenoble · Sites in France
Ages 18–85 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
428 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 67 · Phase 3 52 · Phase 4 17
First in 1990; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 64 across the 328 interventional studies, 90 across the 98 observational. Of the 318 that completed or were terminated, 60 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
121 of 428 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 8 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Parkinson Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT04179695University Hospital, LilleEvaluation of a New Communication Aid Tool to Favor Global Patient Centered Care | 2026-12 |
| NCT07083089Cilcare SASEarly Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR) | 2026-12 |
| NCT06401395DIAMPARKClinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING (AWAKENING) | 2027-01-01 |
| NCT06576713University Hospital, Strasbourg, FranceCombined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism | 2027-01-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 428 studies in Parkinson Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.
Studying the genetic forms of parkinsonian syndromes presents numerous clinical, scientific and therapeutic interests. In clinical practice, identifying the genetic cause in a patient allow to provide genetic counseling and estimate the risk of recurrence in their relatives. Establishing correlations between the genotype and phenotype of patients with genetically determined parkinsonism, allow to better anticipate the evolution of the disease, or even to highlight biomarkers during the presymptomatic phases. Finally, the proteins encoded by the genes implicated in familial parkinsonism represent potential therapeutic targets likely to be modulated by neuroprotective pharmacological agents, even in sporadic Parkinson's disease.
In this work,investigators aimed at elucidating the missing genetic causes of parkinsonism through the application of combined RNA and whole genome sequencing.
Investigators selected 14 patients with early-onset parkinsonism for whom no variant of certain pathogenicity had been identified after exome sequencing.
Patients and their relatives will have a blood sample collection following the inclusion visit for DNA extraction, patients will receive a skin biopsy for fibroblast culture and RNA extraction for RNA sequencing. The genome sequencing will be performed on an Illumina® HiSeq4000 sequencer.
Investigators will also perform skin biopsies on patients for fibroblast cultures in order to extract RNA for RNA sequencing. The choice of fibroblast analysis for the study of the transcriptome is justified by the fact that genes expressed in the brain likely to be associated with neurodegenerative diseases are more frequently expressed in the skin than in the other clinically accessible tissues such as blood. Skin biopsies will be performed by the referring clinicians, and RNA extraction will be carried out using the Quiagen® RNeasy kit.
Transcriptome analysis by RNA sequencing including sequencing and bioinformatics processing of data, including detection of aberrant splicing (LeafCutter), aberrant expressions (DESeq) and identification of variants (GATK + Varank) will also be carried out Genome data will be integrated with data from RNA sequencing. Investigators plan to analyze all 14 patients according to this strategy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Combiner whole genome and RNA sequencing
High-throughput DNA and RNA sequencing
Genetic diagnosis rate
To estimate the rate of genetic diagnoses obtained by genome sequencing coupled with RNA sequencing within a cohort of patients presenting with early onset or familial parkinsonian syndromes without molecular diagnosis.
Time frame: 18 months
Genes implicated
Estimate the proportion of patients carrying pathogenic or probably pathogenic variants in each of the genes identified in this work
Time frame: 18 months
Contribution of RNA sequencing
Estimate the proportion of pathogenic or probably pathogenic variants detected secondarily thanks to the contribution of RNA sequencing and not identified by analysis of the genome taken in isolation.
Time frame: 18 months
Genotype and Phenotype correlation
Estimate the proportion of patients presenting specific clinical, biological and imaging characteristics for each identified genetic cause (genotype/phenotype correlation).
Time frame: 18 months
New genetic causes
Describe new molecular mechanisms of parkinsonian syndromes.
Time frame: 18 months
Tolerance
Estimate the proportion of patients experiencing an adverse event related to the procedure.
Time frame: 18 months
New associated genes
Describe new genes associated with parkinsonian syndromes.
Time frame: 18 months
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 23 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →